To include your compound in the COVID-19 Resource Center, submit it here.

FDA snubs Cardiome's Brinavess resubmission for AF

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said FDA informed the company that its proposed data package for IV Brinavess

Read the full 188 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE